John Mendlein's Net Worth
John Mendlein's net worth is estimated to be at least $2,306,130.69 as of 12/23/2024. CoreStreet's estimation of John Mendlein's net worth is based on their sale of stock and current holding of stock.
John Mendlein is Director at Fate Therapeutics Inc. They have executed at least 11 trades of stock as per SEC Form 4 filings. Their most recent trade was for 36,631 units of FATE stock on 01/13/2023. Their biggest sale was on 03/10/2022 when they sold 31,562 units of Fate Therapeutics Inc stock for $1,105,301.24. They typically trade 1 times per year.
Total value of insider buys:
- $1,169,743.89
Total value of insider sells:
- $1,136,386.80
Most recent insider trade:
- Jan. 13, 2023
John Mendlein's Insider Trading History
| Fate Therapeutics Inc | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|
Jan. 13, 2023 | Director | 36,631 | $5.43 | Buy | $198,906.33 |
Jan. 11, 2023 | Director | 88,048 | $5.67 | Buy | $499,232.16 |
June 3, 2022 | Director | 1,364 | $22.79 | Sell | $31,085.56 |
March 10, 2022 | Director | 31,562 | $35.02 | Sell | $1,105,301.24 |
Oct. 4, 2013 | Director | 16,667 | $6.00 | Buy | $100,002.00 |
| aTyr Pharma Inc | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|
Dec. 21, 2018 | Director | 245,000 | $0.42 | Buy | $102,900.00 |
Aug. 31, 2017 | CEO | 37,736 | $2.65 | Buy | $100,000.40 |
April 24, 2017 | CEO | 124 | $3.00 | Buy | $372.00 |
April 20, 2017 | CEO | 2,552 | $3.00 | Buy | $7,656.00 |
Dec. 19, 2016 | CEO | 69,000 | $2.20 | Buy | $151,800.00 |
April 5, 2016 | CEO | 2,500 | $3.55 | Buy | $8,875.00 |